These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32036339)

  • 1. [α-Synuclein as Diagnostic Biomarker].
    Ono K
    Brain Nerve; 2020 Feb; 72(2):137-141. PubMed ID: 32036339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Alpha-Synuclein in blood and cerebrospinal fluid of patients with alpha-synucleinopathy].
    Ono K; Yamada M
    Rinsho Byori; 2014 Mar; 62(3):241-5. PubMed ID: 24800499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Α-synuclein as a biomarker for early diagnosis of Parkinsonism].
    Ono K; Yamada M
    Rinsho Shinkeigaku; 2013; 53(11):983-5. PubMed ID: 24291853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's and Lewy body dementia CSF biomarkers.
    Parnetti L; Paciotti S; Farotti L; Bellomo G; Sepe FN; Eusebi P
    Clin Chim Acta; 2019 Aug; 495():318-325. PubMed ID: 31051162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies.
    Bargar C; Wang W; Gunzler SA; LeFevre A; Wang Z; Lerner AJ; Singh N; Tatsuoka C; Appleby B; Zhu X; Xu R; Haroutunian V; Zou WQ; Ma J; Chen SG
    Acta Neuropathol Commun; 2021 Apr; 9(1):62. PubMed ID: 33827706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
    Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
    J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease.
    Murakami H; Tokuda T; El-Agnaf OMA; Ohmichi T; Miki A; Ohashi H; Owan Y; Saito Y; Yano S; Tsukie T; Ikeuchi T; Ono K
    BMC Neurol; 2019 Jun; 19(1):113. PubMed ID: 31164098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Oligomer Hypothesis in α-Synucleinopathy.
    Ono K
    Neurochem Res; 2017 Dec; 42(12):3362-3371. PubMed ID: 28828740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].
    Orimo S
    Rinsho Shinkeigaku; 2008 Jan; 48(1):11-24. PubMed ID: 18386627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Autonomic Dysfunction and Skin Biopsy in Dementia with Lewy Bodies].
    Orimo S
    Brain Nerve; 2018 Aug; 70(8):915-927. PubMed ID: 30082501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances alpha-synuclein fibril formation in vitro.
    Ono K; Noguchi-Shinohara M; Yoshita M; Naiki H; Yamada M
    Exp Neurol; 2007 Feb; 203(2):579-83. PubMed ID: 17011551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cerebrospinal fluid and plasma biomarkers for dementia with lewy bodies].
    Kasuga K; Ikeuchi T
    Brain Nerve; 2012 May; 64(5):505-13. PubMed ID: 22570064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies.
    Rossi M; Candelise N; Baiardi S; Capellari S; Giannini G; Orrù CD; Antelmi E; Mammana A; Hughson AG; Calandra-Buonaura G; Ladogana A; Plazzi G; Cortelli P; Caughey B; Parchi P
    Acta Neuropathol; 2020 Jul; 140(1):49-62. PubMed ID: 32342188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
    Jellinger KA; Korczyn AD
    BMC Med; 2018 Mar; 16(1):34. PubMed ID: 29510692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-Synuclein as a Biomarker for Parkinson's Disease.
    Atik A; Stewart T; Zhang J
    Brain Pathol; 2016 May; 26(3):410-8. PubMed ID: 26940058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Protein Conformational Strains-A Key for New Diagnostic Methods of Human Diseases.
    Surguchov A
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies.
    Singer W; Schmeichel AM; Shahnawaz M; Schmelzer JD; Boeve BF; Sletten DM; Gehrking TL; Gehrking JA; Olson AD; Savica R; Suarez MD; Soto C; Low PA
    Ann Neurol; 2020 Sep; 88(3):503-512. PubMed ID: 32557811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
    Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
    Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.